Feb 12 (Reuters) - West Pharmaceutical forecast annual profit above Wall Street estimates on Thursday, after beating fourth-quarter expectations on strong demand for its proprietary products, which ...

Large drugmakers once had more room to absorb failure, both financially and reputationally | Large drugmakers are facing tighter constraints than in the past, as financial, scientific and reputational ...

Prices for GLP-1s are falling fast, forcing companies to adapt.

AstraZeneca announces multibillion dollar investments in China as Big Pharma is increasingly looking east for innovation.

Novartis CEO Vas Narasimhan received $32.4 million in total realized compensation in 2025, a marked increase compared to his take home pay in 2024. Narasimhan received 24.9 million Swiss Francs last ...

Q4 2025 earnings call recap: 2026 guidance, royalty receipts growth outlook, synthetic royalty deals, pipeline catalysts, and ...

Ascendis Pharma A/S reports €684 million revenue and positive 4Q profit; Yorvipath and TransCon CNP drive growth. See why ASND stock is a buy.

Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 millionQ4 2025 operating profit of €10 million and cash flow from ...

SpyGlass Pharma Inc. shares jumped 83% in the biopharmaceutical firm’s trading debut after it raised $150 million in an ...

All pharma brands airing during the Super Bowl got a boost over the broader pharma category, per Verve for Advertisers. Novartis scored the highest among any pharma or health brand on USA Today’s Ad ...

Two weeks after launch, 91% of people had confirmed that they had completed the training. That level of visibility ...